Usefulness of 99mTc-sestamibi scintigraphy in suggesting the therapeutic effect of chemotherapy against gastric cancer

Clinical Cancer Research

Volumn 10, Issue 11, 2004, Pages 3788-3793

  Kawata, Kenji ^a   Kanai, Michiyuki ^a   Sasada, Tetsuro ^a   Iwata, Shingo ^a   Yamamoto, Naritaka ^a   Takabayashi, Arimichi ^a  

^a Kitano Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL; GLYCOPROTEIN P; GLYCOPROTEIN P 170 KDA; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC IMAGING; DRUG ACCUMULATION; DRUG UPTAKE; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MALE; PRIORITY JOURNAL; SCINTIGRAPHY; STOMACH CANCER; METABOLISM; METHODOLOGY; MIDDLE AGED; SCINTISCANNING; STOMACH TUMOR;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CISPLATIN; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; P-GLYCOPROTEIN; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; STOMACH NEOPLASMS; TECHNETIUM TC 99M SESTAMIBI;

EID: 2542539958     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1072-3     Document Type: Article

References (34)

1. Simon SM, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994;91:3497-504.
2. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989;58:137-71.
3. Wackers FJ, Berman DS, Maddahi J, et al. Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989;30:301-11.
4. West DJ, Najm YC, Mistry R, et al. The localization of myocardial ischemia with technetium-99m-methoxyisobutyl-isonitrile and single photon emission computed tomography. Br J Radiol 1989;62:303-13.
5. O'Doherty MJ, Kettle AG, Welles P, Collins RE, Coakley AJ. Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies. J Nucl Med 1992;33:313-8.
6. O'Tuama LA, Treves ST, Larar JN, et al. Thallium-201 versus technetium-99m-MIBI SPECT in evaluation of childhood brain tumors: a within-subject comparison. J Nucl Med 1993;34:1045-51.
7. Hassan IM, Sahweil A, Constantinides C, et al. Uptake and kinetics of Tc-99m hexakis 2 methoxy isobutyl-isonitrile in benign and malignant lesions in the lungs. Clin Nucl Med 1989;14:333-40.
8. Kao CH, Wang SJ, Lin WY, et al. Differentiation of single solid lesions in the lungs by means of single-photon emission tomography with technetium-99m methoxyisobutylisonitrile. Eur J Nucl Med 1993;20:249-54.
9. Maublant J, de Latour M, Metas D, et al. Technetium-99m-sestamibi uptake in breast tumor and associated lymph nodes. J Nucl Med 1996;37:922-5.
10. Nakahara H, Noguchi S, Murakami N, et al. Technetium-99m-sestamibi scintigraphy compared with thallium-201 in evaluation of thyroid tumors. J Nucl Med 1996;37:901-4.
11. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2 methoxyisobutylisonitrile) technetium (I) in cultured mouse fibroblasts. J Nucl Med 1990;31:1646-53.
12. Arbab AS, Koizumi K, Toyama K, Araki T. Uptake of technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 in tumor cell lines. J Nucl Med 1996;37:1551-6.
13. 99mTc-MIBI scintigraphy as an indicator of the chemosensitivity of anthracyclines in patients with breast cancer. Anticancer Res 1998;18:4601-5.
14. Ceriani L, Giovanella L, Bandera M, et al. Semi-quantitative assessment of 99Tcm-sestamibi uptake in lung cancer: relationship with clinical response to chemotherapy. Nucl Med Commun 1997;18:1087-97.
15. Yamamoto Y, Nishiyama Y, Satoh K, et al. Comparative study of technetium-99m-sestamibi and thallium-201 SPECT in predicting chemotherapeutic response in small cell lung cancer. J Nucl Med 1998;39:1626-9.
16. Bom HS, Kim YC, Song HC, et al. Technetium-99m-MIBI uptake in small cell lung cancer. J Nucl Med 1998;39:91-4.
17. Kim YS, Cho SW, Lee KJ, et al. Tc-99m-MIBI SPECT is useful for noninvasively predicting the response of MDR1 gene-encoded P-glycoprotein in patients with hepatocellular carcinoma. Clin Nucl Med 1999;24:874-9.
18. Kao CH, Tsai SC, Wang JJ, et al. Technetium-99m-sestamethoxy-isobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression, multidrug resistance-related protein expression and other prognosis factor. Br J Haematol 2001;113:369-74.
19. Taki J, Sumiya H, Asada N, et al. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy. J Nucl Med 1998;39:1179-84.
20. Bhatnagar A, Vezza PR, Bryan JA, et al. Technetium-99m-sestamibi parathyroid scintigraphy: effect of p-glycoprotein, histology and tumor size on detectability. J Nucl Med 1998;39:1617-20.
21. Leitha T, Glaser C, Lang S. Is early sestamibi imaging in head and neck cancer affected by MDR status, p53 expression, or cell proliferation? Nucl Med Biol 1998;25:539-41.
22. 9mtechnetium-methoxyisobutylisonitrile with histological necrosis following induction chemotherapy or measures of p-glycoprotein expression in high-grade osteosarcoma. Clin Cancer Res 2001;7:3065-70.
23. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma, 2nd English Edition. Gastric Cancer 1999;1:10-24.
24. Piwnica-Worms D, Chiu ML, Budding M, et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977-84.
25. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer 1998;77:353-8.
26. Moretti JL, Cordobes MD, Starzec A, et al. Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells. J Nucl Med 1998;39:1214-8.
27. 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes. Eur J Biochem 1998;15:140-6.
28. 99mTc-MIBI imaging in patients with lung cancer. J Nucl Med 2001;42:1476-83.
29. Chang CS, Huang WT, Yang SS, et al. Effect of P-glycoprotein and multidrug resistance associated protein gene expression on Tc-99m MIBI imaging in hepatocellular carcinoma. Nucl Med Biol 2003;30:111-7.
30. Waxman AD. Thallium-201 and technetium-99m methoxyisobutyl isonitrile (MIBI) in nuclear oncology. In: Sandler MP, Coleman RE, Wackers FJT, et al., editors. Diagnostic nuclear medicine, 3rd ed. Baltimore, MD: Williams and Wilkins; 1996. p. 1261-74.
31. Walters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999;80:269-72.
32. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004.
33. 99mTc-sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours. Anticancer Res 1999;19:2349-53.
34. Chen CC, Meadows B, Regis J, et al. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin Cancer Res 1997;3:545-52.